FindMyKOL
Clinical trialNCT03148275CompletedPhase 2Interventional

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

NCT03148275 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is completed. It studies Trametinib in Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and 1 more condition. The registry lists an enrollment of 44 participants at 36 sites in 1 country. The registry lists a start date of 20 Jun 2017 and a primary completion date of 23 Jun 2023. One of its registered investigators has a FindMyKOL profile.

SponsorNational Cancer Institute (NCI) →Enrollment44Locally Advanced Epithelioid HemangioendotheliomaMetastatic Epithelioid HemangioendotheliomaUnresectable Epithelioid Hemangioendothelioma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03148275
FieldValue
Registry IDNCT03148275
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment44
Registered sites36
Countries1
ConditionsLocally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and Unresectable Epithelioid Hemangioendothelioma
DrugsTrametinib
Start20 Jun 2017
Primary completion23 Jun 2023
Study completion23 Jun 2023
Last update posted26 Nov 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States2 sites
  • Mayo Clinic Hospital in Arizona

    Phoenix

  • Mayo Clinic in Arizona

    Scottsdale

California, United States1 site
  • Stanford Cancer Institute Palo Alto

    Palo Alto

Colorado, United States1 site
  • Uchealth University of Colorado Hospital

    Aurora

Connecticut, United States2 sites
  • Smilow Cancer Center/yale-New Haven Hospital

    New Haven

  • Yale University

    New Haven

Florida, United States1 site
  • Mayo Clinic in Florida

    Jacksonville

Illinois, United States1 site
  • Northwestern University

    Chicago

Kansas, United States1 site
  • University of Kansas Clinical Research Center

    Fairway

Maryland, United States1 site
  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore

Massachusetts, United States4 sites
  • Beth Israel Deaconess Medical Center

    Boston

  • Brigham and Women's Hospital

    Boston

  • Dana-Farber Cancer Institute

    Boston

  • Massachusetts General Hospital Cancer Center

    Boston

Michigan, United States1 site
  • University of Michigan Comprehensive Cancer Center

    Ann Arbor

Minnesota, United States1 site
  • Mayo Clinic in Rochester

    Rochester

Missouri, United States2 sites
  • Siteman Cancer Center at West County Hospital

    Creve Coeur

  • Washington University School of Medicine

    St Louis

Nebraska, United States3 sites
  • Nebraska Medicine-Bellevue

    Bellevue

  • Nebraska Medicine-Village Pointe

    Omaha

  • University of Nebraska Medical Center

    Omaha

New York, United States6 sites
  • Roswell Park Cancer Institute

    Buffalo

  • Memorial Sloan Kettering Cancer Center

    New York

  • Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center

    New York

  • Montefiore Medical Center - Moses Campus

    The Bronx

  • Montefiore Medical Center-Einstein Campus

    The Bronx

  • Montefiore Medical Center-Weiler Hospital

    The Bronx

North Carolina, United States1 site
  • Duke University Medical Center

    Durham

Ohio, United States2 sites
  • Cleveland Clinic Foundation

    Cleveland

  • Ohio State University Comprehensive Cancer Center

    Columbus

Pennsylvania, United States2 sites
  • Fox Chase Cancer Center

    Philadelphia

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh

Tennessee, United States2 sites
  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville

  • Vanderbilt University/ingram Cancer Center

    Nashville

Texas, United States1 site
  • M D Anderson Cancer Center

    Houston

Utah, United States1 site
  • Huntsman Cancer Institute/university of Utah

    Salt Lake City

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesota: 1 siteMN1WisconsinWIMichigan: 1 siteMI1New York: 6 sitesNY6Massachusetts: 4 sitesMA4Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhio: 2 sitesOH2Pennsylvania: 2 sitesPA2New JerseyNJConnecticut: 2 sitesCT2California: 1 siteCA1NevadaNVWyomingWYNebraska: 3 sitesNE3Missouri: 2 sitesMO2KentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizona: 2 sitesAZ2Utah: 1 siteUT1Colorado: 1 siteCO1Kansas: 1 siteKS1ArkansasARTennessee: 2 sitesTN2North Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1Florida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03148275

Each answer restates registry values shown on this page.

What is NCT03148275?

NCT03148275 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Trametinib in Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma and 1 more condition.

Who leads NCT03148275?

The registry names Scott M Schuetze (principal investigator, University of Michigan Comprehensive Cancer Center EDDOP) as the overall official.

Where does NCT03148275 run?

The registry lists 36 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03148275 study?

The registered drug and biological interventions are Trametinib.

When did NCT03148275 end?

The registry lists a primary completion date of 23 Jun 2023 and a study completion date of 23 Jun 2023. The sponsor last updated the record on 26 Nov 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.